341 related articles for article (PubMed ID: 30806082)
1. Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice.
Chukwueke UN; Wen PY
CNS Oncol; 2019 Mar; 8(1):CNS28. PubMed ID: 30806082
[No Abstract] [Full Text] [Related]
2. Response Assessment in Neuro-Oncology Clinical Trials.
Wen PY; Chang SM; Van den Bent MJ; Vogelbaum MA; Macdonald DR; Lee EQ
J Clin Oncol; 2017 Jul; 35(21):2439-2449. PubMed ID: 28640707
[TBL] [Abstract][Full Text] [Related]
3. Clinical controversy: how do you manage germ cell tumors of the CNS?
Ausman JI; Nicholson JC; Takakura K; Albright AL; Friedman WA; Krivoy S
Surg Neurol; 2003 Jul; 60(1):5-7. PubMed ID: 12864995
[No Abstract] [Full Text] [Related]
4. Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice.
Galanis E; Nassiri F; Coy S; Nejad R; Zadeh G; Santagata S
Am Soc Clin Oncol Educ Book; 2018 May; 38():148-157. PubMed ID: 30231374
[TBL] [Abstract][Full Text] [Related]
5. Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints.
Huang RY; Wen PY
Magn Reson Imaging Clin N Am; 2016 Nov; 24(4):705-718. PubMed ID: 27742111
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Brain Tumor Response: RANO and Its Offspring.
Eisele SC; Wen PY; Lee EQ
Curr Treat Options Oncol; 2016 Jul; 17(7):35. PubMed ID: 27262709
[TBL] [Abstract][Full Text] [Related]
7. Imaging Criteria in Neuro-oncology.
Nowosielski M; Wen PY
Semin Neurol; 2018 Feb; 38(1):24-31. PubMed ID: 29548049
[TBL] [Abstract][Full Text] [Related]
8. Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.
Kickingereder P; Isensee F; Tursunova I; Petersen J; Neuberger U; Bonekamp D; Brugnara G; Schell M; Kessler T; Foltyn M; Harting I; Sahm F; Prager M; Nowosielski M; Wick A; Nolden M; Radbruch A; Debus J; Schlemmer HP; Heiland S; Platten M; von Deimling A; van den Bent MJ; Gorlia T; Wick W; Bendszus M; Maier-Hein KH
Lancet Oncol; 2019 May; 20(5):728-740. PubMed ID: 30952559
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Gandhi L; Ou SI; Shaw AT; Barlesi F; Dingemans AC; Kim DW; Camidge DR; Hughes BGM; Yang JC; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S
Eur J Cancer; 2017 Sep; 82():27-33. PubMed ID: 28646771
[TBL] [Abstract][Full Text] [Related]
10. Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.
Sharma M; Juthani RG; Vogelbaum MA
Chin Clin Oncol; 2017 Aug; 6(4):37. PubMed ID: 28841799
[TBL] [Abstract][Full Text] [Related]
11. Management of Central Nervous System Tumors.
Kaley T; Nabors LB
J Natl Compr Canc Netw; 2019 May; 17(5.5):579-582. PubMed ID: 31117044
[TBL] [Abstract][Full Text] [Related]
12. Disparities in Neuro-Oncology.
Michaelson NM; Watsula A; Bakare-Okpala A; Mohamadpour M; Chukwueke UN; Budhu JA
Curr Neurol Neurosci Rep; 2023 Dec; 23(12):815-825. PubMed ID: 37889427
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic molecular markers in common adult gliomas.
Rivera AL; Pelloski CE
Expert Rev Mol Diagn; 2010 Jul; 10(5):637-49. PubMed ID: 20629512
[TBL] [Abstract][Full Text] [Related]
14. Patterns of care for adults with newly diagnosed malignant glioma.
Chang SM; Parney IF; Huang W; Anderson FA; Asher AL; Bernstein M; Lillehei KO; Brem H; Berger MS; Laws ER;
JAMA; 2005 Feb; 293(5):557-64. PubMed ID: 15687310
[TBL] [Abstract][Full Text] [Related]
15. Neuro-oncology: a selected review of ASCO 2012 abstracts.
Chamberlain MC
CNS Oncol; 2012 Nov; 1(2):127-30. PubMed ID: 25057862
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system tumors: what have we learned and where are we heading?
Laws ER
CA Cancer J Clin; 1998; 48(6):327-9, 322. PubMed ID: 9838897
[TBL] [Abstract][Full Text] [Related]
17. Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
Jaspan T; Morgan PS; Warmuth-Metz M; Sanchez Aliaga E; Warren D; Calmon R; Grill J; Hargrave D; Garcia J; Zahlmann G
AJNR Am J Neuroradiol; 2016 Sep; 37(9):1581-7. PubMed ID: 27127006
[TBL] [Abstract][Full Text] [Related]
18. Advances in the management of pediatric central nervous system tumors.
Abdullah S; Qaddoumi I; Bouffet E
Ann N Y Acad Sci; 2008 Sep; 1138():22-31. PubMed ID: 18837879
[TBL] [Abstract][Full Text] [Related]
19. Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology.
Foster JB; Alonso MM; Sayour E; Davidson TB; Persson ML; Dun MD; Kline C; Mueller S; Vitanza NA; van der Lugt J
Neoplasia; 2023 Aug; 42():100909. PubMed ID: 37244226
[TBL] [Abstract][Full Text] [Related]
20. Proton therapy patterns of care among pediatric and adult patients with CNS tumors.
Tseng YD; Hartsell W; Tsai H; Badiyan S; Wang CJ; Rossi C; Kotecha R; Vora S; Vargas C; Larson G; Halasz LM
Neuro Oncol; 2018 Oct; 20(11):1556-1557. PubMed ID: 30085163
[No Abstract] [Full Text] [Related]
[Next] [New Search]
